Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2019 | 03-2019 | 12-2018 | 09-2018 | 06-2018 | |
| Sales | 387,763 | 400,745 | 353,214 | 391,706 | 372,845 |
| Cost of Goods | 77,436 | 89,182 | 75,019 | 78,893 | 79,019 |
| Gross Profit | 310,327 | 311,563 | 278,195 | 312,813 | 293,826 |
| Operating Expenses | 352,117 | 365,696 | 316,362 | 329,447 | 319,108 |
| Operating Income | -41,354 | -53,951 | -38,148 | -15,741 | -25,263 |
| Interest Expense | 6,866 | 6,727 | 7,746 | 12,131 | 12,225 |
| Other Income | 6,325 | 7,721 | 2,583 | 8,459 | 8,311 |
| Pre-tax Income | -41,895 | -52,957 | -43,311 | -19,413 | -29,177 |
| Income Tax | -4,460 | 3,516 | -39,661 | -6,793 | -12,385 |
| Net Income Continuous | -37,435 | -56,473 | -3,650 | -12,620 | -16,792 |
| Net Income | $-37,435 | $-56,473 | $-3,650 | $-12,620 | $-16,792 |
| EPS Basic Total Ops | -0.21 | -0.32 | -0.03 | -0.07 | -0.09 |
| EPS Basic Continuous Ops | -0.21 | -0.32 | -0.02 | -0.07 | -0.09 |
| EPS Diluted Total Ops | -0.21 | -0.32 | -0.02 | -0.07 | -0.09 |
| EPS Diluted Continuous Ops | -0.21 | -0.32 | -0.02 | -0.07 | -0.09 |
| EBITDA(a) | $-15,629 | $-32,415 | $-13,843 | $11,414 | $-5,088 |